FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W48484498> ?p ?o ?g. }

• W48484498 endingPage "P154" @default.
• W48484498 startingPage "P153" @default.
• W48484498 abstract "Lymphatic malformations (LMs) are low-flow congenital lesions that consist of cysts of varying size. Sclerotherapy with intralesional bleomycin and OK-432 has been reported to yield dramatically beneficial results for this disorder. However, inflammation-related symptoms are often seen after treatment with these sclerosing agents. On the other hand, polidocanol (POL) is reportedly associated with fewer allergic and inflammatory reactions. Up to now, however, very few reports have documented the use of POL microfoam for treatment of LMs. This study was performed to assess the efficacy and safety of POL microfoam sclerotherapy for LMs.Between 2003 and 2016, cases were identified from a prospectively compiled database on low-flow congenital vascular malformations before undertaking a retrospective electronic chart review. Patients were included if they had LMs that had been treated by POL microfoam sclerotherapy. The location, size, and type of LMs were assessed using ultrasound and magnetic resonance imaging. Twenty-gauge venous catheters were inserted into the lymphatic space under ultrasound visualization. The LMs were then fully aspirated if they were macrocystic in form. Microfoam composed of 3% POL was then injected under ultrasound guidance. Microcystic LMs were treated by direct injection with POL microfoam under ultrasound guidance. The outcome was assessed by clinical examination combined with findings of postsclerotherapy imaging using ultrasound and magnetic resonance imaging.During a 13-year period, 32 patients met the inclusion criteria. These were 11 (34%) male patients and 21 (66%) female patients with a mean age of 18 years. The LMs were localized to the head and neck (47%), the trunk (38%), and the extremities (15%). The lesions were subdivided into macrocystic (56%), mixed macrocystic and microcystic (31%), and microcystic (13%) LMs. The average lesion size was 6.6 × 4.6 × 3.0 cm. The mean number of treatment sessions was 2.8 (range, 1-15), with a mean foam volume of 4.6 (range, 1-10) mL. Excellent (47%) and moderate (41%) responses were seen in 88% of the patients. Notably, half of the patients achieved excellent or moderate resolution with a single treatment session. Intralesional hemorrhage occurred in four patients (13%) but resolved spontaneously. Only one patient with mixed macrocystic and microcystic LMs developed post-therapy infection. However, the other patients did not develop any post-therapy inflammation-related symptoms, including fever, pain, and marked swelling.Percutaneous sclerotherapy using POL microfoam appears to be safe and effective for treatment of LMs. Ultrasound-guided POL microfoam sclerotherapy should be considered for such lesions, particularly those that are exclusively macrocystic." @default.
• W48484498 created "2016-06-24" @default.
• W48484498 creator A5000937519 @default.
• W48484498 creator A5004830589 @default.
• W48484498 creator A5013263666 @default.
• W48484498 creator A5027592821 @default.
• W48484498 creator A5061524606 @default.
• W48484498 creator A5062587128 @default.
• W48484498 date "2005-08-01" @default.
• W48484498 modified "2023-09-30" @default.
• W48484498 title "Treatment of Cervicofacial Lymphatic Malformations with OK-432 Sclerotherapy" @default.
• W48484498 doi "https://doi.org/10.1016/j.otohns.2005.05.345" @default.
• W48484498 hasPublicationYear "2005" @default.
• W48484498 type Work @default.
• W48484498 sameAs 48484498 @default.
• W48484498 citedByCount "0" @default.
• W48484498 crossrefType "journal-article" @default.
• W48484498 hasAuthorship W48484498A5000937519 @default.
• W48484498 hasAuthorship W48484498A5004830589 @default.
• W48484498 hasAuthorship W48484498A5013263666 @default.
• W48484498 hasAuthorship W48484498A5027592821 @default.
• W48484498 hasAuthorship W48484498A5061524606 @default.
• W48484498 hasAuthorship W48484498A5062587128 @default.
• W48484498 hasConcept C126838900 @default.
• W48484498 hasConcept C141071460 @default.
• W48484498 hasConcept C142724271 @default.
• W48484498 hasConcept C143409427 @default.
• W48484498 hasConcept C143753070 @default.
• W48484498 hasConcept C181152851 @default.
• W48484498 hasConcept C2777857975 @default.
• W48484498 hasConcept C2778230777 @default.
• W48484498 hasConcept C2780950165 @default.
• W48484498 hasConcept C71924100 @default.
• W48484498 hasConceptScore W48484498C126838900 @default.
• W48484498 hasConceptScore W48484498C141071460 @default.
• W48484498 hasConceptScore W48484498C142724271 @default.
• W48484498 hasConceptScore W48484498C143409427 @default.
• W48484498 hasConceptScore W48484498C143753070 @default.
• W48484498 hasConceptScore W48484498C181152851 @default.
• W48484498 hasConceptScore W48484498C2777857975 @default.
• W48484498 hasConceptScore W48484498C2778230777 @default.
• W48484498 hasConceptScore W48484498C2780950165 @default.
• W48484498 hasConceptScore W48484498C71924100 @default.
• W48484498 hasIssue "2" @default.
• W48484498 hasLocation W484844981 @default.
• W48484498 hasOpenAccess W48484498 @default.
• W48484498 hasPrimaryLocation W484844981 @default.
• W48484498 hasRelatedWork W2030459371 @default.
• W48484498 hasRelatedWork W2065508700 @default.
• W48484498 hasRelatedWork W2094285008 @default.
• W48484498 hasRelatedWork W2114092941 @default.
• W48484498 hasRelatedWork W2154362091 @default.
• W48484498 hasRelatedWork W2397294672 @default.
• W48484498 hasRelatedWork W2408027614 @default.
• W48484498 hasRelatedWork W2781990019 @default.
• W48484498 hasRelatedWork W3087664852 @default.
• W48484498 hasRelatedWork W4256001871 @default.
• W48484498 hasVolume "133" @default.
• W48484498 isParatext "false" @default.
• W48484498 isRetracted "false" @default.
• W48484498 magId "48484498" @default.
• W48484498 workType "article" @default.